Despite the fact that there were only a few case reports, all of them recommended the continuation of ART in the case of IRIS-induced thrombocytopenia [9]. Corticosteroids remain the cornerstone of management, with adjuvants including intravenous immunoglobulin, thrombopoietin receptor agonists (eltrombopag), anti-D immune globulin, rituximab, and, in rare cases, splenectomy [9]. The gene discussed is MPL; the disease is Thrombocytopenia.